Changes to Clarity’s Board of Directors
Sydney, Australia 1 February 2023 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that Cheryl Maley has joined Clarity’s Board of Directors as a Non-Executive Director. Dr Gillies O’Bryan-Tear has resigned from the…